Depatuxizumab mafodotin explained

Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.^{[1] [2]} It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.Web site: Antibody-drug conjugates in the spotlight - The Antibody Society. 14 October 2016. antibodysociety.org. ^[3]

This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.^[4]

In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.^[5] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.^[6] Phase I results were presented at ASCO in 2016.^[6]

References

1. http://www.ama-assn.org/resources/doc/usan/x-pub/depatuxizumab-mafodotin.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin
2. World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115 . WHO Drug Information . 30 . 2 . 2016 . World Health Organization .
3. Nagayama A, Ellisen LW, Chabner B, Bardia A . Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments . Targeted Oncology . 12 . 6 . 719–739 . December 2017 . 29116596 . 10.1007/s11523-017-0535-0 . 1012740 .
4. Web site: AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019 . abbvie.com . 20 May 2019.
5. Web site: Depatuxizumab mafodotin. en.pharmacodia.com.
6. Web site: Depatuxizumab mafodotin - AbbVie - AdisInsight. adisinsight.springer.com.